A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements.
The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement.
” We first met Zentiva during BIO-Europe in 2019. Since then, we have had a continuous dialogue as they see substantial potential in our drug delivery platforms for several of their development projects. With this agreement in place, we now look forward to future collaborations”, says Andreas Bhagwani, CEO of Nanologica.
Zentiva is a producer of high-quality and affordable medicines, serving people in Europe and beyond. The Company headquartered in Prague, Czech Republic has a network of productions sites and employs more than 4 500 employees.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org